2025
Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
Caturegli G, Canavan M, Ayoade O, Woodard G, Boffa D, Resio B. Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer. Journal Of Clinical Oncology 2025, 43: 8072-8072. DOI: 10.1200/jco.2025.43.16_suppl.8072.Peer-Reviewed Original ResearchStage III non-small cell lung cancerIII non-small cell lung cancerNon-small cell lung cancerThree-year overall survivalNonsurgical optionsDefinitive radiationLocal therapyOverall survivalClinical stage III non-small cell lung cancerLung cancerClinical stage III patientsStage III NSCLC patientsStage III lung cancerSquamous cell carcinoma patientsStage III lung adenocarcinomaIII NSCLC patientsInitiation of radiationNon-operative formsCharlson-Deyo scoreIII lung cancerNational Cancer DatabaseStage III patientsTreated with radiationCell carcinoma patientsKaplan-Meier methodRadiation toxicity and survival in patients with interstitial lung disease and non-small cell lung cancer: A case control study
Justet A, Jackson L, Bardon M, Lerouge D, Césaire M, Loiseau C, Bergot E, Christy F, Thariat J. Radiation toxicity and survival in patients with interstitial lung disease and non-small cell lung cancer: A case control study. Cancer/Radiothérapie 2025, 29: 104622. PMID: 40311519, DOI: 10.1016/j.canrad.2025.104622.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseNon-small cell lung cancerProgression-free survivalCell lung cancerOverall survivalLung diseaseCase-control studyLung cancerCentral reviewOligometastatic non-small cell lung cancerMedian progression-free survivalCase-control study of patientsPrevalence of interstitial lung diseaseConsecutive lung cancer patientsIntensity-modulated radiotherapyStereotactic body radiotherapyMedian overall survivalThree-dimensional radiotherapyScore of fibrosisPrognosis of patientsGround-glass patternInterstitial pulmonary fibrosisStudy of patientsLung cancer patientsCancer treatment characteristicsRecent Survival Gains in Stage IV NSCLC by Sociodemographic Strata
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clinical And Research Reports 2025, 6: 100798. DOI: 10.1016/j.jtocrr.2025.100798.Peer-Reviewed Original ResearchNon-small cell lung cancerStage IV non-small cell lung cancerIV non-small cell lung cancerStage IV NSCLC patientsIV NSCLC patientsCell lung cancerMedian survivalNSCLC patientsLung cancerNon-small cell lung cancer patientsNational Cancer DatabaseKaplan Meier methodTwo-year survivalStratified Cox analysisAdjusted mortality riskMeier methodCancer DatabaseCox analysisEra 1NSCLC treatmentSurvival gainChemotherapy administrationNon-Hispanic blacksPatientsHispanic patientsThe Role of the Interventional Radiologist in Stopping Bleeding in Cancer Patients
Fish A, Madoff D. The Role of the Interventional Radiologist in Stopping Bleeding in Cancer Patients. Current Oncology Reports 2025, 1-7. PMID: 40120057, DOI: 10.1007/s11912-025-01663-5.Peer-Reviewed Original ResearchUterine artery embolizationBronchial artery embolizationArtery embolizationBronchial arterial chemoembolizationMalignancy-related bleedingLife-threatening complicationsImproved long-term controlMultidisciplinary approachLong-term controlTumor bleedingArterial chemoembolizationSuperselective embolizationIschemic complicationsEmbolization techniquesInterventional radiologistsControl hemorrhageLung cancerHemostatic solutionsCancer patientsEmbolizationEndovascular interventionStop bleedingImprove outcomesBleedingHemorrhagePrecision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Nousias O, Mandell J, Anderson K, Townsend J. Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC. Lung Cancer 2025, 202: 108487. PMID: 40090261, DOI: 10.1016/j.lungcan.2025.108487.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsCell lung cancerLung cancer patientsEvolution of drug resistanceLung cancerDrug resistanceCancer patientsTyrosine kinase inhibitor therapyKinase inhibitor therapyTyrosine kinase inhibitorsPersonalized therapeutic strategiesTKI therapyInhibitor therapyTherapeutic failureResistance mutationsTherapeutic efficacyKinase inhibitorsAPOBEC mutationsTherapeutic strategiesTreatment efficacyCancer progressionImprove outcomesCancerHSA Adductomics in the Shanghai Women’s Health Study Links Lung Cancer in Never-Smokers with Air Pollution, Redox Biology, and One-Carbon Metabolism
Imani P, Grigoryan H, Dudoit S, Shu X, Wong J, Zhang L, Zhang J, Hu W, Cai Q, Gao Y, Blechter B, Rahman M, Zheng W, Rothman N, Lan Q, Rappaport S. HSA Adductomics in the Shanghai Women’s Health Study Links Lung Cancer in Never-Smokers with Air Pollution, Redox Biology, and One-Carbon Metabolism. Antioxidants 2025, 14: 335. PMCID: PMC11939640, DOI: 10.3390/antiox14030335.Peer-Reviewed Original ResearchPolycyclic aromatic hydrocarbonsNever-smokersAir pollutionLung cancerOne-carbon metabolismAirborne fine particulate matterLung adenocarcinomaUrinary polycyclic aromatic hydrocarbonsFine particulate matterShanghai Women's Health StudyWomen's Health StudySmoking-related cancersReactive oxygen speciesIncidence of lung adenocarcinomaAromatic hydrocarbonsLung cancer casesParticulate matterEast Asian womenHealth StudyCancer casesAsian womenDietary factorsPollutionHuman serum albuminHigher incidenceQuantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.
Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, Liu M, Aung T, Scott L, Chan N, Burela S, Schillo J, Liebler D, Hill S, Morrison R, Vathiotis I, Syrigos K, Goldberg S, Politi K, Rimm D. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer. Clinical Cancer Research 2025 PMID: 40047548, DOI: 10.1158/1078-0432.ccr-24-3347.Peer-Reviewed Original ResearchNon-small cell lung cancerAntibody-drug conjugatesAntibody-drug conjugate targetsEGFR mutationsCell lung cancerEGFR expressionQuantitative immunofluorescenceWild-type non-small cell lung cancerLung cancerAssociated with EGFR mutationsAssociated with EGFR expressionTissue microarray cohortAssociation of HER2Management of patientsAssay limitProportion of casesMutation statusTROP2 expressionMicroarray cohortEGFRQuantitative protein expressionTreatment sequencePatientsCell linesWild-typeTop advances of the year: Small cell lung cancer
Shields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerExtensive-stage small cell lung cancerCell lung cancerLung cancerLimited-stage small cell lung cancerFrequency of disease relapseTiming of immunotherapyCancer-related mortalityLong-term survivalAntibody-drug conjugatesNeuroendocrine subtypeDisease relapseAggressive biologyMetastatic spreadInferior outcomesImproved survivalImmunotherapyTherapeutic breakthroughConsolidation treatmentCancerPrecision medicineBiomarker selectionSurvivalLurbinectedinForward-thinking approachCorrigendum to ‘The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer’ [Journal of Thoracic Oncology, Volume 19 Issue 5 (2024) 786-802]
Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y, Marino M, Marom E, Putora P, Singh N, Suárez F, Rami-Porta R, Detterbeck F, Eberhardt W, Asamura H, Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee M. Corrigendum to ‘The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer’ [Journal of Thoracic Oncology, Volume 19 Issue 5 (2024) 786-802]. Journal Of Thoracic Oncology 2025 PMID: 39927917, DOI: 10.1016/j.jtho.2025.01.017.Peer-Reviewed Original ResearchNinth EditionLung cancerReal-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform
Exarchos A, Bourla A, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams E, Gaffey S, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol N, Chiang A. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemporary Clinical Trials Communications 2025, 44: 101446. PMID: 40027276, PMCID: PMC11869879, DOI: 10.1016/j.conctc.2025.101446.Peer-Reviewed Original ResearchCirculating tumor DNAClinico-genomic datasetsRecurrent metastatic non-small cell lung cancerExtensive-stage small-cell lung cancerLung cancerMetastatic non-small cell lung cancerStandard line of therapyCirculating tumor DNA testingSmall-cell lung cancerNon-small cell lung cancerLines of therapyCell lung cancerClinico-genomic databaseSerial blood samplesPre-specified timepointsCommunity-based research sitesTumor DNAPatient cohortClinical dataStage IVGenomic profilingPrognostic biomarkerAcademic centersUS sitesBlood samplesA Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS Mutations
Riess J, Lara M, Luxardi G, de Rodas M, Shimoda M, Kelly K, Lara P, Beckett L, Monjazeb A, Schalper K, Maverakis E, Gandara D. A Phase I/IB Trial of Pembrolizumab and Trametinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Enriched for KRAS Mutations. JTO Clinical And Research Reports 2025, 100806. DOI: 10.1016/j.jtocrr.2025.100806.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerMEK inhibitionAdverse eventsProgressive diseaseKRAS mutationsMyeloid-derived suppressor cellsTrametinib 2 mgDose-escalation studyPlatinum-based chemotherapyImmune cell alterationsTumor immune microenvironmentPhase 1 studyCell lung cancerHigh-parameter flow cytometryArm BEscalation studyPartial responseArm ASuppressor cellsImmune microenvironmentPembrolizumabTrametinibQuantitative immunofluorescenceLung cancerLow-Dose CT of the Chest: Is High-Risk Population Screening for Both Lung Cancer and Cardiovascular Disease Possible?
Fuss C. Low-Dose CT of the Chest: Is High-Risk Population Screening for Both Lung Cancer and Cardiovascular Disease Possible? Radiology 2025, 314: e250215. PMID: 39964272, DOI: 10.1148/radiol.250215.Peer-Reviewed Original ResearchLobectomy verses Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation
Woodard G, Grau-Sepulveda M, Onaitis M, Udelsman B, David E, Jacobs J, Kosinski A, Blasberg J, Boffa D. Lobectomy verses Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation. The Annals Of Thoracic Surgery 2025 PMID: 39864772, DOI: 10.1016/j.athoracsur.2025.01.004.Peer-Reviewed Original ResearchNon-small cell lung cancerSublobar resectionCell lung cancerLung cancerNodal upstagingImproved survivalHealthy patientsNode-negative non-small cell lung cancerThe Society of Thoracic Surgeons databaseRandomized trialsSociety of Thoracic Surgeons databaseAssociated with improved survivalEarly-stage lung cancerFewer lymph nodesInferior to survivalSublobar resection groupLymph node resectionThoracic Surgeons databaseLymph node evaluationProspective randomized trialsKaplan-Meier analysisForced expiratory volumeCT1 N0Pathologic upstagingNodal evaluationUsing natural language processing to identify emergency department patients with incidental lung nodules requiring follow‐up
Moore C, Socrates V, Hesami M, Denkewicz R, Cavallo J, Venkatesh A, Taylor R. Using natural language processing to identify emergency department patients with incidental lung nodules requiring follow‐up. Academic Emergency Medicine 2025, 32: 274-283. PMID: 39821298, DOI: 10.1111/acem.15080.Peer-Reviewed Original ResearchNatural language processingIncidental lung nodulesFollow-upChest CTsCT reportsF1 scoreLung nodulesEmergency departmentLanguage processingFollow-up of incidental findingsIncidental findingNatural language processing developersAbsence of malignancyMetrics of precisionNatural language processing pipelineNatural language processing metricsChest CT reportsRecommended follow-upEmergency department patientsFollow-up rateLanguage modelLung cancerReduce errorsMalignancyDepartment patientsInfective Complications of Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) and Clinical Biomarkers: A Concise Review
Bosgana P, Ampazis D, Vlachakos V, Tzouvelekis A, Sampsonas F. Infective Complications of Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) and Clinical Biomarkers: A Concise Review. Diagnostics 2025, 15: 145. PMID: 39857029, PMCID: PMC11764001, DOI: 10.3390/diagnostics15020145.Peer-Reviewed Original ResearchEndobronchial ultrasound transbronchial needle aspirationInfective complicationsLung cancerInterventional pulmonology proceduresIncidence of lung cancerNeedle aspirationPrompt treatmentInfective pathologyRisk factorsClinical biomarkersRising incidenceComplicationsRising incidence of lung cancerCancerBiomarkersConcise reviewMediastinumIncreasing numberPatientsLungReviewClinicDiagnosis
2024
Mechanisms of immunotherapy resistance in small cell lung cancer
Nie Y, Schalper K, Chiang A. Mechanisms of immunotherapy resistance in small cell lung cancer. Cancer Drug Resistance 2024, 7: n/a-n/a. PMID: 39802951, PMCID: PMC11724353, DOI: 10.20517/cdr.2024.154.Peer-Reviewed Original ResearchSmall-cell lung cancerImmune checkpoint inhibitorsSociety for Immunotherapy of CancerImmunotherapy resistanceTumor microenvironmentPrimary resistanceAcquired resistancePrimary resistance to immune checkpoint inhibitorsLung cancerResistance to immune checkpoint inhibitorsMechanisms of immunotherapy resistanceSmall cell lung cancerImmunosuppressive immune cellsImmunotherapy to chemotherapyResistance to immunotherapySociety for ImmunotherapyImmunotherapy of cancerAggressive neuroendocrine tumorCell lung cancerCheckpoint inhibitorsTumor immunogenicityEffective immunotherapyNeuroendocrine tumorsPoor prognosisAntigen presentationA novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy
Zhang J, Qu Z, Xiao X, Adelson D, Wang F, Wei A, Harata-Lee Y, Cui J, He D, Xie L, Sun L, Li J, Huang Z, Aung T, Yao H, Lin L. A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy. Heliyon 2024, 11: e41104. PMID: 39844968, PMCID: PMC11750466, DOI: 10.1016/j.heliyon.2024.e41104.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR-TKI-resistant cell linesNon-small cell lung cancerInhibition of drug resistanceLung cancerEpidermal growth factor receptor tyrosine kinase inhibitor resistanceDrug resistanceGrowth factor receptor tyrosine kinase inhibitorsCell linesReceptor tyrosine kinase inhibitorsEGFR-TKI resistanceResistance to gefitinibCell lung cancerFirst-line treatmentPI3K/AKT/mTOR pathwayMortality of lung cancerEGFR mutationsTreatment failureMolecular mechanismsDose-dependentlyKinase inhibitorsFlow cytometryAnticancer effectsGefitinibH1650 cellsExposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis
Sassano M, Seyyedsalehi M, Kappil E, Zhang S, Zheng T, Boffetta P. Exposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis. Environmental Research 2024, 266: 120606. PMID: 39672496, DOI: 10.1016/j.envres.2024.120606.Peer-Reviewed Original ResearchPooled relative riskRelative riskHead and neckEstimate pooled relative risksConfidence intervalsExposure to per-Evidence of publication biasNatural log-unit increaseThyroid cancerCase-control studyPolyfluoroalkyl substances exposuresAssociated with lungPublication biasSystematic reviewPositive associationMeasured serum levelsMeta-analysisSerum PFAS levelsTesticular cancerProspective studyAssociationSerum levelsPFAS exposureExposure assessmentLung cancerThe evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review
Zolfaghari E, Dhanasopon A, Woodard G. The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review. Journal Of Thoracic Disease 2024, 0: 0-0. PMID: 39831209, PMCID: PMC11740046, DOI: 10.21037/jtd-24-245.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorEarly-stage non-small cell lung cancerAnaplastic lymphoma kinaseAdjuvant therapyCell lung cancerEarly-stage patientsSurgical resectionOverall survivalAdjuvant chemotherapyLung cancerSurvival benefit of adjuvant therapyAdjuvant platinum-based chemotherapyBenefit of adjuvant therapyHigh-risk pathologic featuresStage IB tumorsNational Clinical Trials RegistryPlatinum-based chemotherapyHigh-risk featuresCirculating tumor DNALandscape of adjuvant therapyLung cancer recurrenceGrowth factor receptorClinical Trials RegistryAdjuvant osimertinibEstimated exposure to endotoxin and circulating immunological markers among male farmers in the Biomarkers of Exposure and Effect in Agriculture study
Ezennia S, Freeman L, Chang V, Xie S, Sandler D, Andreotti G, Parks C, Friesen M, Hofmann J. Estimated exposure to endotoxin and circulating immunological markers among male farmers in the Biomarkers of Exposure and Effect in Agriculture study. Occupational And Environmental Medicine 2024, 81: 635-638. PMID: 39746796, PMCID: PMC11821429, DOI: 10.1136/oemed-2024-109646.Peer-Reviewed Original ResearchConceptsExposure to endotoxinImmune markersAssociated with reduced lung cancer riskEndotoxin exposureEstimated geometric mean ratiosCirculating immune markersMacrophage-derived chemokine/CCL22Reduced risk of lung cancerLevels of fibroblast growth factor-2Decreased levelsMultiplex bead-based assayRisk of lung cancerExposure-response mannerExposed to endotoxinAssociated with increased levelsLung cancer riskFibroblast growth factor-2Immunological alterationsGrowth factor 2Serum levelsImmunological markersSIL-4RLung cancerBead-based assayMultivariate linear regression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply